E. Di Salle - Concepedia

Author

E. Di Salle

Nerviano Medical Sciences

Also Known As

E DI SALLE, E Di Salle, E di Salle, E. DI SALLE, E. Di Salle, E. di Salle, E.di Salle, Enrico Di Salle, Enrico di Salle

Publications

4.1K

Citations

H-Index

Concepts

All Affiliations

Nerviano Medical Sciences Mario Negri Institute for Pharmacological Research Haukeland University Hospital Ospedale San Carlo Fondazione IRCCS Istituto Nazionale dei Tumori

About

E. Di Salle is an author at Nerviano Medical Sciences specializing in medicine, pharmacology, and aromatase.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	27	44	2.5K
2	Biochemistry	12	12	515
3	Natural Sciences	6	6	280
4	Health Sciences	5	5	163
5	Education	1	1	22

E. Di Salle

Publications

3.8K

Citations

H-Index

Page 1

	Year	Citations
Exemestane Is Superior to Megestrol Acetate After Tamoxifen Failure in Postmenopausal Women With Advanced Breast Cancer: Results of a Phase III Randomized Double-Blind Trial Manfred Kaufmann, Emilio Bajetta, Luc Dirix, Journal of Clinical Oncology	2000	525
Activity of Exemestane in Metastatic Breast Cancer After Failure of Nonsteroidal Aromatase Inhibitors: A Phase II Trial Per Eystein Lønning, Emilio Bajetta, Robin Murray, Journal of Clinical Oncology	2000	318
In vivo inhibition of aromatization by exemestane, a novel irreversible aromatase inhibitor, in postmenopausal breast cancer patients. Jürgen Geisler, Nicholas King, Gun Anker, PubMed Bolus InjectionBreast OncologyGynecologyPharmacotherapyMg P.o	1998	316
Biochemical and pharmacogenetic dissection of human steroid 5??-reductase type II Nick Makridakis, E. Di Salle, Juergen Reichardt Pharmacogenetics	2000	208
Endocrine and clinical effects of exemestane (PNU 155971), a novel steroidal aromatase inhibitor, in postmenopausal breast cancer patients: a phase I study. Dag Clement Johannessen, Terje Engan, E. Di Salle, PubMed Breast OncologyGynecologyPharmacotherapyEndocrine OncologyOncology	1997	193
Phase I and endocrine study of exemestane (FCE 24304), a new aromatase inhibitor, in postmenopausal women. T.R. Jeffry Evans, E. Di Salle, G. Ornati, PubMed GynecologyPharmacotherapyReproductive EndocrinologyTransient EosinophiliaSteroid Metabolism	1992	150
6-Methylenandrosta-1,4-diene-3,17-dione (FCE 24304): A new irreversible aromatase inhibitor D. Giudici, G. Ornati, G. Briatico, Journal of Steroid Biochemistry Medicinal ChemistryBiochemistryNatural SciencesMedicineAromatase	1988	148
Third-line hormonal treatment with exemestane in postmenopausal patients with advanced breast cancer progressing on aminoglutethimide: a phase ii multicentre multinational study Beat Thürlimann, R. Paridaens, D. Serin, European Journal of Cancer Breast OncologyPhase IiMedicinePharmacologyGynecology	1997	145
Hypertensive and Renin-Suppressing Activities of Propranolol in Hypertensive Patients Gastone Leonetti, G Mayer, Alberto Morganti, Clinical Science HypertensionCardiovascular PharmacologyOral PropranololPharmacotherapyBlood Pressure	1975	114
Multicenter, Phase II Trial of Exemestane as Third-Line Hormonal Therapy of Postmenopausal Women With Metastatic Breast Cancer Stefanie A Jones, Charles L. Vogel, A. Arkhipov, Journal of Clinical Oncology	1999	113

Page 1